Journey Medical Corp DERM.OQ DERM.O is expected to show a fall in quarterly revenue when it reports results on May 14 for the period ending March 31 2025
The Scottsdale Arizona-based company is expected to report a 7.5% decrease in revenue to $12.055 million from $13.03 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Journey Medical Corp is for a loss of 24 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Journey Medical Corp is $9.75, above its last closing price of $6.88.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.35 | -0.15 | Beat | 57.4 | |
Sep. 30 2024 | -0.14 | -0.15 | -0.17 | Missed | -15.3 |
Jun. 30 2024 | -0.14 | -0.14 | -0.17 | Missed | -18.6 |
Mar. 31 2024 | -0.23 | -0.23 | -0.53 | Missed | -125.5 |
Dec. 31 2023 | -0.09 | -0.08 | -0.12 | Missed | -56.5 |
Sep. 30 2023 | -0.11 | -0.15 | 0.80 | Beat | 616.1 |
Jun. 30 2023 | -0.35 | -0.33 | -0.29 | Beat | 13.4 |
Mar. 31 2023 | -0.45 | -0.45 | -0.57 | Missed | -27.6 |
This summary was machine generated May 12 at 20:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)